Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk